Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Abstract
Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve its primary endpoint of improving recurrence-free survival (RFS). The biomarker companion study BIOSTORM aims to define (A) predictors of recurrence prevention with sorafenib and (B) prognostic factors with B level of evidence.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 02, 2018
- Source ID
- 10.1136/gutjnl-2018-316408
Entities
People
- Adina Emilia Croitoru
- Agrin Moeini
- Augusto Villanueva
- Carol Pena
- Chris Verslype
- Daniela Sia
- Edward Gane
- Gar-yang Chau
- Gerold Meinhardt
- Han Chu Lee
- Joong-won Park
- Jordi Bruix
- Jordi Camps
- Josep M. Llovet
- Laia Bassaganyas
- Leonardo Rodriguez-carunchio
- Luigi Lupo
- Manel Solé
- Manuel De La Mata
- Robert Montal
- Roser Pinyol
- Sara Torrecilla
- Sasan Roayaie
- Simone Strasser
- Swan N. Thung
- Tadatoshi Takayama
- Umberto Cillo
- Vincenzo Mazzaferro
- Yoshihiro Sakamoto
- Zhongyang Zhang
Organizations
- Agency for Administration of University and Research
- American Association for the Study of Liver Diseases
- Bayer HealthCare
- Carlos III Health Institute
- Generalitat of Catalonia
- Horizon 2020
- National Cancer Institute
- Onyx Pharmaceuticals
- Samuel Waxman Cancer Research Foundation
- Spanish Association Against Cancer
- United States Department of Defense
- Worldwide Cancer Research